Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 8/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437071 | 0.81 | ALDH1A1 (0.64) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5442804 | 0.79 | LMNA (0.56) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5437131 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5452955 | 0.77 | ALDH1A1 (0.65) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5452709 | 0.77 | ALDH1A1 (0.59) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5435794 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5445092 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5438209 | 0.75 | ALDH1A1 (0.49) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5452939 | 0.74 | KDM4E (0.89) | ALDH1A1KDM4EGAAGLAHPGD | |
| SCHEMBL5440062 | 0.72 | KDM4E (0.64) | ALDH1A1KDM4EGAAGLAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | claimed |
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | ALDH1A1 1767/4885KDM4E 1686/4885GAA 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.